Key Highlights

  • UroGen Pharma (NASDAQ:URGN) traded at USD 28.16 on November 4, 2026, with an intraday decline of 18.14%, the same day it released third quarter numbers and lowered its 2026 JELMYTO Revenue outlook.
  • ZUSDURI net product sales hit USD 68.0 million in the quarter, a 35% rise from the second quarter, whereas JELMYTO revenue slipped to USD 21.0 million from USD 25.7 million a year before.
  • Management trimmed 2026 JELMYTO guidance to roughly USD 90 million from the previous USD 97 million to USD 101 million, blaming a one-time CMS-linked adjustment and rival trial enrollment.
  • The net loss shrank to USD 1.5 million from USD 33.3 million, yet cash and marketable securities declined to USD 90.5 million, and the Balance Sheet carries a shareholders' deficit.

Intraday Drivers for UroGen Pharma (down USD 6.24, 18.14%)

UroGen Pharma (NASDAQ:URGN) was quoted at USD 28.16 intraday on November 4, 2026, off 18.14%. The implied previous close of USD 34.40 (calculated) means the decline equals USD 6.24 per share. Published market data showed around 617,480 shares trading, about 0.54 times the stock's typical pace, with market Capitalization near USD 1.38 billion. The timing lines up with the company release issued at 8:00 a.m. ET on November 4, 2026, followed by a conference call at 10:00 a.m. ET. Published coverage said total revenue came in under analyst estimates, though the consensus number was not verified here. Heavy selling on lighter than usual Volume points to holders reacting to the guidance change rather than a broad wave of fresh buying or selling.

Third Quarter Detail and the Lower JELMYTO Forecast

Total third quarter revenue reached USD 89.0 million, compared with USD 27.5 million a year earlier, and ZUSDURI supplied USD 68.0 million of that. Activated sites of care for ZUSDURI rose to 1,538 from 1,444 as of June 30, 2026, unique prescribers grew to 662 from 452, and 331 prescribers were repeat users, roughly half the total. JELMYTO sales came to USD 21.0 million, which absorbed a one-time unfavorable gross-to-net hit of about USD 1.5 million. Management now projects 2026 JELMYTO net product revenue near USD 90 million, below the earlier USD 97 million to USD 101 million, attributing the change to that adjustment and competitive trial enrollment that reduces patient starts in low-grade upper tract urothelial cancer.

Balance Sheet, Pipeline and Investor Focus

The company posted a net loss of USD 1.5 million, or USD 0.03 per share, versus USD 33.3 million the prior year. Cash, equivalents and marketable securities totaled USD 90.5 million on September 30, 2026, down from USD 120.5 million on December 31, 2025, while total liabilities of USD 397.1 million topped total Assets of USD 271.9 million. Operating Expense guidance sits at USD 260 million to USD 270 million, near the top of that range. In the pipeline, the FDA accepted the UGN-103 application in October 2026 with a PDUFA goal date of June 14, 2027, and a Phase 3 study in high-risk disease is slated to begin in the fourth quarter. A lower guidance figure can weigh on valuation, since JELMYTO provides steady revenue that helps cover Debt service while ZUSDURI ramps up.

Where Things Stand

The selloff in UroGen Pharma (NASDAQ:URGN) seems tied to the November 4, 2026 results, where robust ZUSDURI expansion was overshadowed by a weaker JELMYTO outlook and a shrinking cash cushion. Upcoming checkpoints include the 10-Q filing, how quickly ZUSDURI adds prescribers and activated sites, and progress toward the June 14, 2027 UGN-103 decision date. Intraday moves can reverse as analysts refresh their models after the call, and the stock stays sensitive to launch execution, reimbursement changes and competing trials.